85-1477-03　Brimonidine-d4 D-Tartrate (5-Bromo-N-(4,5-dihydro-1H-imidazol-d4-2-yl)-6-quinoxalinamine D-Tartrate, ?5-Bromo-6-(2-imidazolin-d4-2-ylamino)quinoxaline, UK-14304-18-d4, AGN-190342-LF-d4, ?Alphagan-d4) 1mg　B2755-01

特徴

• Brimonidine D-Tartrate is an alpha2 receptor agonist. It is a drug used to treat glaucoma and acts via decreasing aqueous humor synthesis.
• Melting Point:205-207.5°C (decomposes)
• Solubility:DMSO, Methanol (sparingly)
• Atmosphere:Air
• Method for Determining Identity:Proton NMR Spectroscopic Analysis and Mass Spectrometric Analysis
• TLC Conditions:SiO2; Dichloromethane: Methanol: NH4OH (90:10:1). Visualized with UV and KMnO4. Single spot; Rf=0.3
• Storage and Stability:May be stored at RT for short-term only. Long-term storage is recommended at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

仕様

• Size：1mg
• Source Antigen：Synthetic
• Grade：Highly Purified
• Purity：Chemical Purity: 98%; Isotopic Purity: 99%
• Form：Off-white to pale yellow solid
• Molecular Formula：C₁₁H₆D₄BrN₅ • C ₄H₆O₆
• Molecular Weight Non Ab：446.26
• EU Commodity Code：38220090
• この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
• 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]